A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe

被引：0

作者：

Rossari, F. ^{[1
]}

Tada, T. ^{[2
]}

Shimose, S. ^{[3
]}

Kudo, M. ^{[4
]}

Yoo, C. ^{[5
]}

Cheon, J. ^{[6
]}

Finkelmeier, F. ^{[7
]}

Lim, H. Y. ^{[8
]}

Presa, J. ^{[9
]}

Masi, G. ^{[10
]}

Bergamo, F. ^{[11
]}

Amadeo, E. ^{[12
]}

Vitiello, F. ^{[13
]}

Foti, S. ^{[14
]}

Camera, S. ^{[12
]}

Persano, M. ^{[15
]}

Stefanini, B. ^{[16
]}

Scartozzi, M. ^{[17
]}

Rimini, M. ^{[12
]}

Gardini, A. Casadei ^{[12
]}

机构：

[1] UniSR Univ Vita & Salute San Raffaele Milano, Dept Med Oncol, SR Tiget, Milan, Italy

[2] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Japan

[3] Kurume Univ Hosp, Div Gastroenterol, Dept Med, Kurume, Japan

[4] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[5] Univ Ulsan, Dept Med Oncol, Asan Med Ctr, Seoul, South Korea

[6] Ulsan Univ Hosp, Div Hematol & Oncol, Ulsan, South Korea

[7] Goethe Univ Frankfurt am Main, Gastroenterol Dept, Campus Westend, Frankfurt, Germany

[8] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

[9] Ras os Montes & Alto Douro Hosp Ctr, Liver Unit, Vila Real, Portugal

[10] Pisa Univ, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[11] IOV Ist Oncol Veneto IRCCS, Oncol 1, Padua, Italy

[12] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[13] IRCCS Osped San Raffaele, Oncol, Milan, Italy

[14] IRCCS Osped San Raffaele, Dept Oncol, Milan, Italy

[15] AOU Cagliari Osped Civile, Dept Med Oncol, Cagliari, Italy

[16] Imperial Coll London, Oncol, Hammersmith Campus, London, England

[17] Univ Cagliari, Dept Med Oncol, Cagliari, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.191

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

182P

引用

页码：S82 / S82

页数：1

共 50 条

[21] Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort
Jost-Brinkmann, Fabian
Demir, Muenevver
Wree, Alexander
Luedde, Tom
Loosen, Sven H.
Mueller, Tobias
Tacke, Frank
Roderburg, Christoph
Mohr, Raphael
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (11) : 1313 - 1325
[22] ANALYSIS OF FACTORS PREDICTING THE REAL-WORLD EFFICACY OF ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Ha, Chang Won
Paik, Yong-Han
Song, Byeong Geun
HEPATOLOGY, 2024, 80
[23] Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma
Song, Byeong Geun
Goh, Myung Ji
Kang, Wonseok
Sinn, Dong Hyun
Gwak, Geum-Youn
Choi, Moon Seok
Lee, Joon Hyeok
Paik, Yong-Han
GUT AND LIVER, 2024, 18 (04) : 709 - 718
[24] Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab
Hsu, Chiun
Ducreux, Michel
Zhu, Andrew X.
Qin, Shukui
Ikeda, Masafumi
Kim, Tae-You
Galle, Peter R.
Finn, Richard S.
Chen, Ethan
Ma, Ning
Hu, Youyou
Li, Lindong
Cheng, Ann-Lii
LIVER CANCER, 2023, 12 (01) : 44 - 56
[25] Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
Ben Khaled, Najib
Moeller, Marie
Jochheim, Leonie S.
Leyh, Catherine
Ehmer, Ursula
Boettcher, Katrin
Pinter, Matthias
Balcar, Lorenz
Scheiner, Bernhard
Weich, Alexander
Leicht, Hans Benno
Zarka, Valentina
Ye, Liangtao
Schneider, Julia
Piseddu, Ignazio
Oecal, Osman
Rau, Monika
Sinner, Friedrich
Venerito, Marino
Gairing, Simon Johannes
Foerster, Friedrich
Mayerle, Julia
Toni, Enrico N. De
Geier, Andreas
Reiter, Florian P.
JHEP REPORTS, 2024, 6 (06)
[26] Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
Rimini, M.
Rimassa, L.
Ueshima, K.
Burgio, V
Shigeo, S.
Tada, T.
Suda, G.
Yoo, C.
Cheon, J.
Pinato, D. J.
Lonardi, S.
Scartozzi, M.
Iavarone, M.
Di Costanzo, G. G.
Marra, F.
Solda, C.
Tamburini, E.
Piscaglia, F.
Masi, G.
Cabibbo, G.
Foschi, F. G.
Silletta, M.
Pressiani, T.
Nishida, N.
Iwamoto, H.
Sakamoto, N.
Ryoo, B-Y
Chon, H. J.
Claudia, F.
Niizeki, T.
Sho, T.
Kang, B.
D'Alessio, A.
Kumada, T.
Hiraoka, A.
Hirooka, M.
Kariyama, K.
Tani, J.
Atsukawa, M.
Takaguchi, K.
Itobayashi, E.
Fukunishi, S.
Tsuji, K.
Ishikawa, T.
Tajiri, K.
Ochi, H.
Yasuda, S.
Toyoda, H.
Ogawa, C.
Nishimur, T.
ESMO OPEN, 2022, 7 (06)
[27] Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience
Sinner, Friedrich
Pinter, Matthias
Scheiner, Bernhard
Ettrich, Thomas Jens
Sturm, Niklas
Gonzalez-Carmona, Maria A.
Waidmann, Oliver
Finkelmeier, Fabian
Himmelsbach, Vera
De Toni, Enrico N.
Ben Khaled, Najib
Mohr, Raphael
Fruendt, Thorben Wilhelm
Kuetting, Fabian
van Boemmel, Florian
Lieb, Sabine
Krug, Sebastian
Bettinger, Dominik
Schultheiss, Michael
Jochheim, Leonie S.
Best, Jan
Mueller, Christian
Keitel, Verena
Venerito, Marino
CANCERS, 2022, 14 (23)
[28] Concurrent transarterial chemoembolization plus atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: Interim analysis from a multicenter real-world study (CHANCE 023).
Zhu, Haidong
Lu, Jian
Teng, Gao-Jun
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 542 - 542
[29] Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
Shen, Xiao
Zhang, Jin-Xing
Liu, Jin
Liu, Sheng
Shi, Hai-Bin
Cheng, Yuan
Zhang, Qing-Qiao
Yin, Guo-Wen
Zu, Qing-Quan
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1993 - 2003
[30] ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): REAL-WORLD EXPERIENCE FROM A US COMMUNITY ONCOLOGY NETWORK
Cosgrove, David
Tan, Amie
Hernandez, Sairy
Mahrus, Sami
Osterland, Andrew
Murphy, John
Loaiza-Bonilla, Arturo
HEPATOLOGY, 2022, 76 : S1308 - S1309

← 1 2 3 4 5 →